Medipharm Labs Corp T.LABS

Q3.

[alleyesonme]

https://stratcann.com/financials/medipharm-labs-reports-increased-revenue-decreased-losses-in-q3-2024/

[Lvlchange]

Broken record of nothing.  

[alleyesonme]

It's not the big news, breakout Q3 many including myself thought it may be but...it's not bad either.  

[alleyesonme]

LOL! what!?! 40 mil a year to keep going?..try 4!...2025 profitable..years into the pharma journey..already beginning to pay..epidiolex launch is soon IMO...400k in German flower in three months...124k all 2023..wheels are turning..still bullish on MPL. 

[Starkicker]

Alleyes, you should keep a pretty low profile on here. In Aug 2023 you said if this wasn't at 70 cents by summer 2024 you'd leave the forum. You haven't been right about ANYTHING for three years. Shhhhhhh.

[alleyesonme]

My stock price projections were wrong..so was every single holder of this Corp..who bought expecting the price to be unchanged years on end?...you must be forgetting as soon as the CBD FDA drug masterfile was announced I immediately stated it was for an epidiolex generic...you thought that was crazy talk...who was right?...you clearly have no idea on anything, ...you just posted LABS annual burn

[Starkicker]

You justed posted their operational costs are $4M annually.  One more incorrect fact. You should follow your space buddy and mdjbrown pumper buddies and disappear as you promised.. But then, it doesn't seem like integrity is your thing. 

[alleyesonme]

Furthermore, 70c a share is a market cap of 300m. When you factor in epidiolex sales numbers in the U.S, and the massive chunk first to Market generics take of that...6month no competition prize for first to market generics enforced by the FDA....I cannot find any other Corp with the certs/facility to bring this to market today...it's not unreasonable to project 100m easy for the MPL top line.

[QContinuum1]

Let's focus more on the tangible current opportunities that are not being realized and less on the what-if catalysts that may or may not hit any time soon. Contrary to the belief of others, marginal growth in markets like Germany or Australia where we've heard for literal years that it will be the next big thing, isn't where this business should be at with proper focus. 

[QContinuum1]

Literally this.  Nothing new, nothing to see here.  Which, IMO, is not good. And despite what others here might think, anyone that has invested in this stock and has held long term ought to have stuck with index etfs.  I know I should have.  Opportunity costs being what they are.

[Starkicker]

Working in highly regulated markets is a slow burn, doesn't matter who your partners are. It will take years to get traction. Just hope the $13M in cash is enough to hold the fort until profitability because we know it costs ~$40M a year to keep this thing going. 

[QContinuum1]

True across the board.  Just would have hoped/thought/expected that Medipharm would have got a running start, in Germany at least given the Stada deal being literally years old now.  Guess not, but onward and upward.  I'm a bit unnerved on what tax loss looks like this year however.